Wednesday, February 27, 2019

Axial Biotherapeutics Finds $25M For Parkinson's, Autism Treatments

Pasadena-based Axial Biotherapeutics, a biotechnology company which is focused on developing treatments for Parkinson's disease and Autism Spectrum Disorder, has raised $25M in its Series B funding round, the company announced this morning. The funding was led by new investor Seventure Partners, via its Health For Life Capital fund, and also

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.